Mizocler (Mizolastine)

Mizolastine, the active ingredient in Mizocler, is an antihistamine presented as an oral tablet for oral administration. It selectively blocks peripheral H1‑receptors, thereby reducing histamine‑mediated symptoms such as sneezing, itching, and rash in patients with allergic rhinitis or chronic urticaria and are commonly prescribed for seasonal and perennial forms of the disease, providing symptomatic relief and improving quality of life.

GNH USA supplies Mizocler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity across markets.

Mizocler (mizolastine) is employed in the treatment of allergic disorders mediated by histamine activation, primarily targeting conditions of the upper respiratory tract and the skin where histamine release causes discomfort. - Allergic rhinitis: relieves nasal congestion, sneezing, itching and watery eyes associated with seasonal or perennial allergic rhinitis. - Chronic urticaria: reduces the number and intensity of hives and associated itching in patients with persistent urticaria.

Mizocler may be associated with a range of adverse reactions, varying from mild and transient to rare but serious.

Common Side Effects: - Drowsiness: mild sleepiness that may affect alertness. - Headache: transient pain often resolving without intervention. - Dry mouth: reduced salivation causing throat discomfort. - Fatigue: general feeling of tiredness. - Nausea: mild stomach upset. - Dizziness: light‑headed sensation, especially when standing quickly.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat requiring immediate medical attention. - Severe skin rash or Stevens‑Johnson‑like reactions. - Anaphylaxis: rapid, life‑threatening allergic reaction. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals. - Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury.

Before prescribing Mizocler, clinicians should consider several safety aspects. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: unknown excretion in milk; weigh maternal benefit against possible infant exposure. - Renal impairment: dose adjustment may be required in severe dysfunction. - Elderly patients: monitor for increased sedation or dizziness. - Concomitant CNS depressants: avoid or use with caution as additive drowsiness may occur. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Mizocler can interact with other medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: may potentiate antihistaminic effects and cause excessive sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase mizolastine plasma concentrations. - Alcohol: additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Other antihistamines: may enhance antiallergic effect and increase risk of drowsiness. - CNS depressants such as benzodiazepines or opioids: monitor for heightened sedation. - Theophylline: may increase risk of tachycardia when combined.